The pioneers for oxMIF
We discovered it, we named it, we are drugging it!
OncoOne has overcome the limitations of targeting macrophage migration inhibitory factor by harnessing the high specificity of the structural isoform, oxidized macrophage migration inhibitory factor (oxMIF), for sites of inflammation and tumors. We are focused on developing multiple proprietary drug modalities to leverage oxMIF’s potential as a target for systemic treatment of colorectal, ovarian and lung cancers, as well as for chronic inflammatory diseases.
Our Founders & Pioneers of oxMIF
Randolf Kerschbaumer, Michael Thiele, and Alexander Schinagl, our founders, made a significant breakthrough in uncovering a disease-related and druggable isoform of one of the most pivotal drivers of innate and adaptive immunity: the macrophage migration inhibitory factor (MIF). This new target, termed the oxidized macrophage migration inhibitory factor (oxMIF), was identified, and named by our founders due to its emergence as a product of post-translational modification within the pro-oxidative environment present in local inflammation and solid tumors.
In collaboration with the entire OncoOne team, our founders are committed to the development of pioneering and best-in-class therapeutics targeting oxMIF, the druggable isoform of MIF.

Our Leadership Team
Equipped with a successful track-record in early-stage drug development, as well as a deep understanding of the target itself, OncoOne’s leadership team will advance a pipeline based on oxMIF’s promise in oncology and chronic inflammation.
Our team is highly committed to our shared goal of developing breakthrough cancer therapeutics. As our company continues to grow, we are looking for individuals with a passion for science who want to join our team and bring new solutions to underserved indications.
Scientific Advisory Board
Public Grants
Our mission is supported by excellent public grant partners.
Collaborators
We value and proudly collaborate with top-tier academic and industry partners.
Head offices
in Vienna (Austria) and Boston (USA)
Cooperation partners
and a diverse team from across the globe with a united mission